The Unaudited Standalone Financial Results along with Statement of Asset & Liabilities and Cash Flow Statement for the quarter and half year ended September 30, 2025 and took note of the ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.3 pts more than Nifty Microcap 250 and 3.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Coral Laboratories Ltd reported its unaudited standalone financial results for the quarter and half year ended September 30, 2025. Revenue from operations fell sharply year-on-year — Q2 revenue dropped to ₹1,903.48 lakhs from ₹3,222.87 lakhs (down ~41%), while H1 revenue fell to ₹3,785.63 lakhs from ₹6,388.45 lakhs (down ~41%). Profit after tax also declined: Q2 PAT stood at ₹582.01 lakhs versus ₹637.98 lakhs last year, and H1 PAT nearly halved to ₹838.18 lakhs from ₹1,518.41 lakhs. H1 EPS came in at ₹23.46 compared to ₹42.50 in the year-ago period. A ₹32.25 lakh one-time provision for earlier-year income tax was recorded as an exceptional item in Q2. Importantly, the company has a new statutory auditor — S C Mehra & Associates LLP replaced M/s M. A. Parekh & Associates, who retired at the AGM on September 26, 2025. Operating cash flow turned positive at ₹1,257.69 lakhs in H1 FY26 versus a small outflow last year.
The steep drop in both revenue and profits is a clear negative for shareholders, suggesting significant business headwinds. The mid-year change of statutory auditor alongside weak numbers may warrant closer scrutiny, though the clean (unmodified) limited review and essentially debt-free balance sheet provide some comfort.